- Home
- NKTX vs INMB Comparison
NKTX vs INMB Comparison
Compare NKTX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- INMB
- Stock Information
- Founded
- NKTX 2015
- INMB 2015
- Country
- NKTX United States
- INMB United States
- Employees
- NKTX N/A
- INMB N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- INMB Health Care
- Exchange
- NKTX Nasdaq
- INMB Nasdaq
- Market Cap
- NKTX 170.8M
- INMB 176.5M
- IPO Year
- NKTX 2020
- INMB 2019
- Fundamental
- Price
- NKTX $2.00
- INMB $7.52
- Analyst Decision
- NKTX Strong Buy
- INMB Strong Buy
- Analyst Count
- NKTX 6
- INMB 3
- Target Price
- NKTX $15.00
- INMB $24.33
- AVG Volume (30 Days)
- NKTX 2.4M
- INMB 252.9K
- Earning Date
- NKTX 03-26-2025
- INMB 03-27-2025
- Dividend Yield
- NKTX N/A
- INMB N/A
- EPS Growth
- NKTX N/A
- INMB N/A
- EPS
- NKTX N/A
- INMB N/A
- Revenue
- NKTX N/A
- INMB $14,000.00
- Revenue This Year
- NKTX N/A
- INMB N/A
- Revenue Next Year
- NKTX N/A
- INMB N/A
- P/E Ratio
- NKTX N/A
- INMB N/A
- Revenue Growth
- NKTX N/A
- INMB N/A
- 52 Week Low
- NKTX $1.31
- INMB $4.32
- 52 Week High
- NKTX $11.84
- INMB $12.72
- Technical
- Relative Strength Index (RSI)
- NKTX 59.36
- INMB 44.72
- Support Level
- NKTX $1.31
- INMB $7.89
- Resistance Level
- NKTX $2.34
- INMB $8.94
- Average True Range (ATR)
- NKTX 0.15
- INMB 0.65
- MACD
- NKTX 0.05
- INMB -0.06
- Stochastic Oscillator
- NKTX 66.99
- INMB 25.65
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.